Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 16Active not recruiting 5Not yet recruiting 2Completed 2Terminated 1Suspended 1No longer available 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 46Neoplasms 34Breast Neoplasms 34Melanoma 26Neoplasm Metastasis 24Leukemia, Myeloid, Acute 21Colorectal Neoplasms 20Prostatic Neoplasms 19Lung Neoplasms 17Multiple Myeloma 16Ovarian Neoplasms 14Recurrence 13Myelodysplastic Syndromes 13Lymphoma, Non-Hodgkin 13Squamous Cell Carcinoma of Head and Neck 12Carcinoma, Renal Cell 12Uterine Cervical Neoplasms 11Lymphoma, Large B-Cell, Diffuse 11Carcinoma, Hepatocellular 11Urinary Bladder Neoplasms 10Pancreatic Neoplasms 10Glioblastoma 10Brain Neoplasms 10Stomach Neoplasms 8Head and Neck Neoplasms 8Triple Negative Breast Neoplasms 7Rectal Neoplasms 7Lymphoma, Follicular 7Lymphoma 7Hodgkin Disease 7

Interventions

atezolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Adenocarcinoma of Lung × 90 days × Clear all
NCT04432207 2026-03-25

A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer

Imugene Limited

Phase 1 Terminated
24 enrolled
Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡